Department of Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
Department of Medicine, Zuyderland Medical Center, Sittard-Geleen, Heerlen, The Netherlands.
Curr Hypertens Rep. 2018 Apr 10;20(4):35. doi: 10.1007/s11906-018-0829-3.
Randomized trials have failed to show clinical benefit in patients with atherosclerotic renal artery stenosis who were treated with angioplasty with or without stenting. However, these studies were done in patients with a high-grade stenosis. This paper examines whether there are arguments to consider patients with low-grade stenosis for angioplasty.
Patients with low-grade (< 50%) atherosclerotic renal artery stenosis have an excess risk for cardiovascular and renal complications. This could be related to inflammatory factors being generated by the stenotic kidney. Moreover, even a kidney with low-grade stenosis clears less or produces more of the natural nitric oxide inhibitor ADMA. Patients with low-grade atherosclerotic renal artery stenosis have an increased risk for a variety of complications. In addition, the abnormality is progressive. There is a case for setting up a prospective trial to examine whether angioplasty confers benefit in patients with low-grade renal artery stenosis.
血管成形术伴或不伴支架置入治疗粥样硬化性肾动脉狭窄患者的随机临床试验未能显示临床获益。然而,这些研究是在重度狭窄患者中进行的。本文探讨了是否有理由考虑对低级别狭窄患者进行血管成形术。
低级别(<50%)粥样硬化性肾动脉狭窄患者发生心血管和肾脏并发症的风险增加。这可能与狭窄肾脏产生的炎症因子有关。此外,即使是低级别狭窄的肾脏也会清除更少或产生更多的天然一氧化氮抑制剂 ADMA。低级别粥样硬化性肾动脉狭窄患者发生多种并发症的风险增加。此外,这种异常是进行性的。有理由进行一项前瞻性试验,以检查血管成形术是否对低级别肾动脉狭窄患者有益。